Dabigatran is a useful and widely used drug for stroke prevention in patients with atrial fibrillation. However, it has been reported to cause esophagitis. Herein, we report the case of a 77-year-old man with dabigatran-induced esophagitis with blue pigmentation, which is known to be a rare adverse effect. The patient presented to our hospital with a tightness of the chest and anorexia. Computed tomography revealed a thickening of the entire esophageal wall, with an upper esophageal predominance. Esophagogastroduodenoscopy was performed, which showed that the cervical and upper thoracic esophagus had blue pigmentation with edematous changes, partial narrowing, and longitudinal sloping. We replaced dabigatran with edoxaban, a similar anticoagulation medication. The patient was closely monitored for 1 month after switching to edoxaban. The follow-up esophagogastroduodenoscopy showed marked improvements, revealing resolution of the bluish discoloration and edematous changes, and the patient's complaints regarding the tightness of the chest and anorexia were also resolved. It is important to recognize that such side effects can occur with dabigatran, a drug that is frequently used in daily practice. Considering the fact that strong edematous changes can cause indigo carmine pigmentation associated with dabigatran stagnation, we recommend switching to another anticoagulant if esophagitis occurs during dabigatran administration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352591PMC
http://dx.doi.org/10.1002/deo2.271DOI Listing

Publication Analysis

Top Keywords

dabigatran-induced esophagitis
8
blue pigmentation
8
dabigatran drug
8
edematous changes
8
esophagitis full
4
full circumferential
4
circumferential blue
4
dabigatran
4
pigmentation dabigatran
4
drug stroke
4

Similar Publications

Unlabelled: Dabigatran, a commonly prescribed anticoagulant medication, has been associated with esophagitis, referred to as dabigatran-induced esophagitis (DIE). We report a case of DIE occurring in a patient following left atrial ablation for atrial fibrillation. This case emphasizes the importance of recognizing the possible combined detrimental effects of left atrial ablation and dabigatran on the esophageal mucosa and highlights the clinical and endoscopic characteristics associated with DIE.

View Article and Find Full Text PDF

Dabigatran is a useful and widely used drug for stroke prevention in patients with atrial fibrillation. However, it has been reported to cause esophagitis. Herein, we report the case of a 77-year-old man with dabigatran-induced esophagitis with blue pigmentation, which is known to be a rare adverse effect.

View Article and Find Full Text PDF

Analysis of the clinical characteristics of dabigatran-induced oesophagitis.

Eur J Hosp Pharm

March 2023

Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China

Objectives: Dabigatran-induced oesophagitis has emerged in recent years. However, the incidence and clinical characteristics of patients with dabigatran-induced oesophagitis have not yet been clarified. The aim of this study was to examine the clinical characteristics of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!